EIKO LIFESCIENCES LTD Q3 RESULTS
Tata Elxsi Q1 Results: Net profit falls 3% YoY to Rs 184 crore
Tata Elxsi Q1 Results: Revenue from operations for the reporting period grew by 9% year-on-year, reaching Rs 926 crore compared to Rs 850 crore in the same period last year. Sequentially, net profit for the quarter dropped by 6% from Rs 196 crore in the preceding December quarter. However, revenues increased by 2% quarter-on-quarter. Total expenses for the first quarter rose by 13% year-on-year to Rs 706 crore, compared to Rs 624 crore in the same quarter last year.
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr
Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Q3 results this week: M&M, Coal India, Hindustan Aeronautics, Eicher motors, BHEL and IRCTC
Siemens, Hindalco Industries, Eicher Motors, BHEL, IRCTC, Bosch, Info Edge (India), Oil India, Prestige Estates Projects, Gujarat Gas, ITI, Deepak Nitrite, National Aluminium Company,
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
- Go To Page 1
Supriya Lifesciences Q3 Results: Net profit triples to Rs 30 crore
Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points.
Wipro Q3 Results: Consolidated PAT drops 12% YoY to Rs 2,694 crore; Re 1/share interim dividend announced
Wipro Q3 Results: Wipro reported disappointing Q3 results, with a decline in net profit and revenue. The company's consolidated net profit decreased by nearly 12% YoY to Rs 2,694 crore, while the consolidated revenue dropped 4.4% to Rs 22,205 crore. The board recommended an interim dividend of Re 1 per share. For the nine months ended December, Wipro's consolidated revenue rose by only 0.4% to Rs 67,552 crore, while the net profit declined by nearly 1% to Rs 8,211 crore. Wipro expects revenue from its IT Services business to be in the range of $2.62 billion to $2.67 billion for the quarter ending March.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Zydus Lifesciences Q2 Results: Firm reports 53% YoY jump in net profit at Rs 801 crore
Revenue from operations rose 9.1% YoY to Rs 4369 crore in Q2FY24 compared to Rs 4006 crore in Q2FY23. On QoQ revenue declined 15%. The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 40.6% YoY to Rs 1146 crore. On QoQ, EBITDA dropped 23.9%.
Zydus Q2 Results: Profit jumps on strong domestic, US demand
India's generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Infosys Q2 Results: PAT rises 3% YoY to Rs 6,212 crore; firm trims FY24 revenue guidance
Infosys has reported a 3% YoY growth in consolidated net profit for the quarter ended September. The company's consolidated revenue also grew nearly 7% YoY. Infosys has tweaked its guidance for FY24, expecting revenue growth of 1.0-2.5% in constant currency terms. The company retained its operating margin target of 20-22%. Infosys announced large TCV deals worth $7.7 billion for the quarter and saw a decline in attrition rate.
Zydus Lifesciences Q1 Results: Net profit doubles to Rs 1,087 crore, revenue jumps 30%
US business grew by 57% YoY at Rs 2454 crores. India branded formulations grew by almost 12%, excluding impact of NLEM related price cut affecting some key products
Zydus Lifesciences Q1 Results: Profit more than doubles on US sales growth
Its U.S formulations business saw a revenue growth of 57.4% to 24.54 billion rupees, while India formulations grew by 9.1% to 12.27 billion rupees. India and U.S. sales make up 38% and 48% of Zydus' total revenue, respectively.
Persistent Systems Q1 Results: Profit rises 8% YoY to Rs 229 crore; revenue jumps 23%
Revenue from operations during the first quarter rose 23% year-on-year to Rs 2,321 crore. It was Rs 1,878 crore in the same quarter of last year.
Infosys Q1 Results: PAT rises 11% YoY to Rs 5,945 cr; firm sharply trims FY24 revenue growth guidance
Taking note of the uncertain global environment, the software major sharply cut its FY24 revenue growth estimate. Infosys now sees revenue growing just 1-3.5% in constant currency terms, against 4-7% earlier.
HCL Tech Q1 Results: Profit rises 8% YoY to Rs 3,534 crore, misses estimates
HCLTech’s attrition for the quarter stood at 16.3% compared to 19.5% reported last quarter. The 12-month trailing attrition rate is at 16.3%, compared to 19.5% a quarter ago. Its headcount in the first quarter stood at 223,438 with a drop of 2,506 over the previous quarter, said Ramachandran Sundararajan, chief people officer. The company, however, added 1,597 freshers during the quarter.
TCS Q1 Results: Profit rises 17% YoY to Rs 11,074 crore, beats estimates; revenue up 13%
While the net profit was above the ET Now poll of Rs 10,890 crore, the revenue was tad lower than the estimated Rs 59,500 crore. Sequentially, the topline rose a mere 0.4%, making this the slowest growth in 12 quarters for the country’s largest software exporter. The profit declined nearly 3% from the March quarter.
Q1 earnings: 26 companies that may report over 100% jump in profit
Domestic brokerage Motilal expects Nifty earnings to grow 25% YoY in Q1. Oil and gas sector may report a 3x surge in profit YoY underpinned by the improvement in marketing margins of OMCs. Auto sector’s earnings may surge 11x YoY during the quarter on a low base.
Q1 results this week: TCS, HCL Tech, Wipro, Avenue Supermarts, Angel One and others
The June quarter earnings are seen to be weaker than expected amid uncertain and global environment and a slowdown in discretionary spending by clients
Zydus Lifesciences Q4 Results: Consolidated net profit dips 25% to Rs 297 crore
Zydus Lifesciences Ltd reported a 25.36% decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the
Q3 results impact: Tata Motors, Zomato among over 35 stock upgrades and downgrades
A team of analysts from global brokerage firm Jefferies has raised the FY23 earnings estimates for 47% of 147 companies under its coverage network. Downgrades were made to 46% of companies, resulting in higher upgrades than downgrades for the first time in five quarters.
Zydus Lifesciences Q3 Results: Firm beats profit view on strong sales
The impact of price hikes to mitigate inflationary pressure would be reflected from the fourth quarter onwards in the consumer wellness segment, which accounted for 10% of total revenues in the third quarter, the company said in an exchange filing.
Q3 results this week: L&T, Bajaj Finserv, Sun Pharma, Tech Mahindra, Ashok Leyland and others
Results that will be out on January 30 include Larsen & Toubro, Bajaj Finserv, Tech Mahindra, Bharat Petroleum Corporation, Bajaj Holdings & Investment, GAIL, SRF, Punjab National Bank, REC, Laurus Labs, IIFL Finance, Trident, Exide Industries, Nippon Life India Asset Management, Mazagon Dock Shipbuilders, Welspun as well as Inox Leisure.
These 8 midcap stocks with ‘strong buy’ & ‘buy’ ratings can rally over 25% during volatile Q3 earnings season
In earning seasons equity markets tend to be volatile. Especially at the time when large companies are announcing their quarterly results, volatility quotient tends to see a spike. It is no different this time and given the valuation street is punishing stocks which are missing analyst estimates. At the same time there are stocks, where analysts are positive and projected returns are high. ET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having an average recommendation rating of “buy” or "strong buy". This predefined screener is only available to ET Prime users.
Q3 results this week: ICICI Bank, HUL, Asian Paints, JSW Steel, SBI Life, others
ICICI Prudential Life Insurance, ICICI Lombard General Insurance, Bank of India, Metro Brands, National Aluminium, Tata Investment Corporation, Eris Lifesciences, Network 18 Media & Investments, TV18 Broadcast, Delta Corp, Mastek, Hathway
Wipro Q3 Results: PAT rises 3% YoY to Rs 3,053 cr; co sees FY23 sales growing 11.5-12%
Wipro Q3 Results: Consolidated revenue for the quarter increased 14.3% YoY to Rs 23,229 crore, and was tad higher than the estimated Rs 23,180 crore
TCS Q3 margins may rise on rupee fall, efficiency
TCS is expected to report 12.4% profit growth and 16.7% revenue growth YoY in Q3: ET poll of analysts
Zydus Lifesciences Q1 Results: Net Profit drops 12% YOY to Rs 518 crore
The earnings before interest, tax, depreciation and ammortisation (EBITDA) was Rs 833 crore, a decline of 14.3% YoY. On QoQ, EBITDA rose 16.1%.The EBITDA margins for the quarter dropped 190 basis points to 20.5% in Q1FY23 compared to 24.3% in Q1FY22. On QoQIndia sales saw a drop of 6.5% YoY to Rs 1817 crore in Q1FY23. The formulation business dropped .
Load More
